Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Background to Gilead's $21 Bln acquisition of Immunomedics

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 01, 2021 12:13pm

174 Views

Post# 34185405

RE:RE:RE:RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

YES - Brilliant - since ONCY has setup the dynamics for its Big Pharma acquirer to run a faster and cheaper Phase 3 registration study thus making ONCY more attractive to multiple bidders rather than just one or three who are presently involved and working with ONCY.

<< Previous

Bullboard Posts

Next >>

Globex Mining: Unveiling Québec’s hidden gold and lithium treasures